A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers
ConclusionsThis study failed to demonstrate clinical activity of tasquinimod in heavily pre-treated patients with advanced hepatocellular, ovarian, renal cell, and gastric cancer.Trial registrationNCT01743469.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Gastric (Stomach) Cancer | Gastroenterology | Kidney Cancer | Ovarian Cancer | Ovaries | Renal Cell Carcinoma | Study | Toxicology